Precise Delivery of Biologic Medicines Using Automated Microneedle Pumps
Engineering Tissue Level Targeting of Biologic Drugs via Automated Interfacial Microneedle Pumps
This project is developing a new way to deliver powerful biologic medicines directly into diseased tissues, such as tumors or heart muscle, using tiny, automated pumps.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11133032 on NIH RePORTER |
What this research studies
Many powerful biologic medicines struggle to reach deep into diseased tissues like tumors or heart muscle because of their large size. This means they might not work as well as they could, or they might spread to other parts of the body and cause unwanted side effects. Our project is creating tiny, automated microneedle pumps designed to deliver these important medicines directly and precisely into the target tissue. This new approach aims to ensure the medicine goes exactly where it's needed, in the right amount, to maximize its healing potential while minimizing risks.
Who could benefit from this research
Good fit: Patients with cancers, cardiac diseases, or other conditions where biologic drugs need to be delivered precisely into dense tissues might eventually benefit from this research.
Not a fit: Patients would not receive direct treatment or benefit from this foundational technology development itself, as it focuses on creating a new drug delivery method.
Why it matters
Potential benefit: If successful, this technology could make biologic drugs much more effective for conditions like cancer and heart disease by ensuring they reach the exact diseased tissue with precision.
How similar studies have performed: This project explores a novel approach to understanding and controlling drug flow into tissues, building upon existing concepts of microneedle delivery.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Abramson, Alex — Georgia Institute of Technology
- Study coordinator: Abramson, Alex
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.